[
  {
    "ts": null,
    "headline": "Is CVS’s Reaffirmed 2026 EPS Guidance Amid Medicare Advantage Uncertainty Altering The Investment Case For CVS Health (CVS)?",
    "summary": "CVS Health reported past fourth-quarter 2025 sales of US$34,017 million and revenue of US$105,693 million, with quarterly net income rising to US$2,943 million and diluted EPS from continuing operations at US$2.30, while full-year 2025 net income declined to US$1,768 million despite revenue increasing to US$402.07 billions. The company also confirmed 2026 GAAP diluted EPS guidance of US$5.94–US$6.14 and completed a multi-year US$8,499.97 million buyback program that retired 96,589,826...",
    "url": "https://finnhub.io/api/news?id=1a8a11aa7ea7b0da1d7e722a91e66b4f6ceb1fd7a35b0b39e1386e53ab380f20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770830151,
      "headline": "Is CVS’s Reaffirmed 2026 EPS Guidance Amid Medicare Advantage Uncertainty Altering The Investment Case For CVS Health (CVS)?",
      "id": 139046551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health reported past fourth-quarter 2025 sales of US$34,017 million and revenue of US$105,693 million, with quarterly net income rising to US$2,943 million and diluted EPS from continuing operations at US$2.30, while full-year 2025 net income declined to US$1,768 million despite revenue increasing to US$402.07 billions. The company also confirmed 2026 GAAP diluted EPS guidance of US$5.94–US$6.14 and completed a multi-year US$8,499.97 million buyback program that retired 96,589,826...",
      "url": "https://finnhub.io/api/news?id=1a8a11aa7ea7b0da1d7e722a91e66b4f6ceb1fd7a35b0b39e1386e53ab380f20"
    }
  },
  {
    "ts": null,
    "headline": "Analysts See Multiple Growth Levers For CVS Health In 2026",
    "summary": "CVS reaffirmed fiscal 2026 guidance, and expects strong growth. Analyst views this as positive and maintain a Buy rating.",
    "url": "https://finnhub.io/api/news?id=f8190aa404bfde823815dc7b47eb601731b7d15b4af918dadbcd31b3bf84022e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770823910,
      "headline": "Analysts See Multiple Growth Levers For CVS Health In 2026",
      "id": 139057892,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Chandler--Arizona---April-08-2023cvs-Hea_0.jpeg?width=2048&height=1536",
      "related": "CVS",
      "source": "Benzinga",
      "summary": "CVS reaffirmed fiscal 2026 guidance, and expects strong growth. Analyst views this as positive and maintain a Buy rating.",
      "url": "https://finnhub.io/api/news?id=f8190aa404bfde823815dc7b47eb601731b7d15b4af918dadbcd31b3bf84022e"
    }
  },
  {
    "ts": null,
    "headline": "Humana Earnings Reveal Narrower-Than-Expected Loss. Why the Stock Is Falling.",
    "summary": "Humana shares are down more than 30% since the federal government announced plans last month to keep Medicare Advantage rates nearly flat in 2027.",
    "url": "https://finnhub.io/api/news?id=4f2cbcaefcd5f820497e5f816aa853e2b99af9a2a6dcebefb06e87083e4a57f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770821220,
      "headline": "Humana Earnings Reveal Narrower-Than-Expected Loss. Why the Stock Is Falling.",
      "id": 139045116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Humana shares are down more than 30% since the federal government announced plans last month to keep Medicare Advantage rates nearly flat in 2027.",
      "url": "https://finnhub.io/api/news?id=4f2cbcaefcd5f820497e5f816aa853e2b99af9a2a6dcebefb06e87083e4a57f2"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health (CVS) Q4 2025 Earnings Call Transcript",
    "summary": "David Joyner: Thank you, Larry, and good morning, everyone.  As I close out my first full year as CEO, I'm encouraged by our ongoing work to simplify the health care experience and make health care more affordable and accessible for American families.",
    "url": "https://finnhub.io/api/news?id=739c0607909743364e81f2875c6fe447b0fc9dced1c3084d493023398e686c4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770820026,
      "headline": "CVS Health (CVS) Q4 2025 Earnings Call Transcript",
      "id": 139045198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "David Joyner: Thank you, Larry, and good morning, everyone.  As I close out my first full year as CEO, I'm encouraged by our ongoing work to simplify the health care experience and make health care more affordable and accessible for American families.",
      "url": "https://finnhub.io/api/news?id=739c0607909743364e81f2875c6fe447b0fc9dced1c3084d493023398e686c4e"
    }
  },
  {
    "ts": null,
    "headline": "Revlon Appoints Mario Rivera as Chief Operations Officer",
    "summary": "Revlon Consumer Products LLC (\"Revlon\") today announced the appointment of Mario Rivera as Chief Operations Officer. Rivera, who joins Revlon from CVS Health, will report to Chief Executive Officer Michelle Peluso. He will oversee Revlon's global supply chain, including procurement, planning, manufacturing, distribution, warehousing, transportation and customer logistics. He will officially begin his role on February 16, 2026.",
    "url": "https://finnhub.io/api/news?id=e0b47423617133d611ef145ea0aae3158c02d4dd30ec0d7f480c74fc01253d19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770818400,
      "headline": "Revlon Appoints Mario Rivera as Chief Operations Officer",
      "id": 139045199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Revlon Consumer Products LLC (\"Revlon\") today announced the appointment of Mario Rivera as Chief Operations Officer. Rivera, who joins Revlon from CVS Health, will report to Chief Executive Officer Michelle Peluso. He will oversee Revlon's global supply chain, including procurement, planning, manufacturing, distribution, warehousing, transportation and customer logistics. He will officially begin his role on February 16, 2026.",
      "url": "https://finnhub.io/api/news?id=e0b47423617133d611ef145ea0aae3158c02d4dd30ec0d7f480c74fc01253d19"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Job Growth Tops Forecast, Delays Fed Cut Expectations",
    "summary": "Nonfarm payrolls rose by 130K in January, beating the 70K consensus and well above Decemberâs 48K.",
    "url": "https://finnhub.io/api/news?id=23a41ba0ec63ad57b267ad0f55a0160c22debc6d8e2dea8ea8dfb8e7b8f9e2a4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770813752,
      "headline": "Wall Street Lunch: Job Growth Tops Forecast, Delays Fed Cut Expectations",
      "id": 139046266,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212529986/image_2212529986.jpg?io=getty-c-w1536",
      "related": "CVS",
      "source": "SeekingAlpha",
      "summary": "Nonfarm payrolls rose by 130K in January, beating the 70K consensus and well above Decemberâs 48K.",
      "url": "https://finnhub.io/api/news?id=23a41ba0ec63ad57b267ad0f55a0160c22debc6d8e2dea8ea8dfb8e7b8f9e2a4"
    }
  },
  {
    "ts": null,
    "headline": "Humana Loss Was Narrower Than Expected. Why the Stock Is Falling.",
    "summary": "Humana shares are down more than 30% since the federal government announced plans last month to keep Medicare Advantage rates nearly flat in 2027.",
    "url": "https://finnhub.io/api/news?id=35b1fd6a6d5f5a3693b7de82bfc518bce45aaf0a0b86abf20f79bd227c536da2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770809580,
      "headline": "Humana Loss Was Narrower Than Expected. Why the Stock Is Falling.",
      "id": 139041048,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Humana shares are down more than 30% since the federal government announced plans last month to keep Medicare Advantage rates nearly flat in 2027.",
      "url": "https://finnhub.io/api/news?id=35b1fd6a6d5f5a3693b7de82bfc518bce45aaf0a0b86abf20f79bd227c536da2"
    }
  },
  {
    "ts": null,
    "headline": "Mark Cuban Urges Trump To 'Put His Weight Behind' Josh Hawley, Elizabeth Warren's 'Break Up Big Medicine Act'",
    "summary": "Mark Cuban backs Hawley-Warren &#39;Break Up Big Medicine Act,&#39; urging President Trump to decouple insurers and PBMs to slash healthcare costs.",
    "url": "https://finnhub.io/api/news?id=48631b2ad65b963e7e472d259a83b1e6f320e9745c7ae0bbce52d8309f3e4e6a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770789498,
      "headline": "Mark Cuban Urges Trump To 'Put His Weight Behind' Josh Hawley, Elizabeth Warren's 'Break Up Big Medicine Act'",
      "id": 139042850,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Los-Angeles---Jan-8-Mark-Cuban-At-The-Sp.jpeg?width=2048&height=1536",
      "related": "CVS",
      "source": "Benzinga",
      "summary": "Mark Cuban backs Hawley-Warren &#39;Break Up Big Medicine Act,&#39; urging President Trump to decouple insurers and PBMs to slash healthcare costs.",
      "url": "https://finnhub.io/api/news?id=48631b2ad65b963e7e472d259a83b1e6f320e9745c7ae0bbce52d8309f3e4e6a"
    }
  },
  {
    "ts": null,
    "headline": "CVS Q4 Deep Dive: Pharmacy Turnaround and Regulatory Shifts Shape Outlook",
    "summary": "Diversified healthcare company CVS Health (NYSE:CVS) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 8.2% year on year to $105.7 billion. Its non-GAAP profit of $1.09 per share was 9.4% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=fe93821a3284b5cc4347446c59b5b417c26e2719aa3e195b4e2c0f4c9e53e906",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770788022,
      "headline": "CVS Q4 Deep Dive: Pharmacy Turnaround and Regulatory Shifts Shape Outlook",
      "id": 139042362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Diversified healthcare company CVS Health (NYSE:CVS) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 8.2% year on year to $105.7 billion. Its non-GAAP profit of $1.09 per share was 9.4% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=fe93821a3284b5cc4347446c59b5b417c26e2719aa3e195b4e2c0f4c9e53e906"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Q4 Earnings Call Highlights",
    "summary": "CVS Health (NYSE:CVS) highlighted what executives described as a year of operational and financial progress during the company’s fourth-quarter 2025 earnings call, while also addressing industry cost pressures, Medicare Advantage funding concerns, and the evolving regulatory backdrop for pharmacy be",
    "url": "https://finnhub.io/api/news?id=2f7df0d34bddedba6c0a1b554d8a70c4ab22ae656944b2fd57365165772776da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770779235,
      "headline": "CVS Health Q4 Earnings Call Highlights",
      "id": 139038887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health (NYSE:CVS) highlighted what executives described as a year of operational and financial progress during the company’s fourth-quarter 2025 earnings call, while also addressing industry cost pressures, Medicare Advantage funding concerns, and the evolving regulatory backdrop for pharmacy be",
      "url": "https://finnhub.io/api/news?id=2f7df0d34bddedba6c0a1b554d8a70c4ab22ae656944b2fd57365165772776da"
    }
  }
]